CRIS Current Research Information System

CAVO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.734
AS - Asia 33.051
EU - Europa 22.146
SA - Sud America 2.126
AF - Africa 1.841
OC - Oceania 81
Continente sconosciuto - Info sul continente non disponibili 45
Totale 93.024
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.126
VN - Vietnam 8.963
SG - Singapore 8.769
CN - Cina 8.149
IT - Italia 4.955
GB - Regno Unito 4.756
DE - Germania 2.807
SE - Svezia 2.276
HK - Hong Kong 2.065
BR - Brasile 1.545
FR - Francia 1.528
IN - India 1.431
RU - Federazione Russa 1.115
NL - Olanda 972
KR - Corea 834
IE - Irlanda 826
FI - Finlandia 666
BD - Bangladesh 638
UA - Ucraina 547
JP - Giappone 499
CI - Costa d'Avorio 476
ZA - Sudafrica 474
TG - Togo 365
CA - Canada 363
EE - Estonia 313
AR - Argentina 233
ID - Indonesia 231
BG - Bulgaria 215
JO - Giordania 210
AT - Austria 209
PH - Filippine 208
CH - Svizzera 190
SC - Seychelles 182
BE - Belgio 175
TH - Thailandia 158
PL - Polonia 146
MX - Messico 136
TR - Turchia 132
IQ - Iraq 129
NG - Nigeria 122
ES - Italia 117
EC - Ecuador 101
TW - Taiwan 100
PK - Pakistan 77
IR - Iran 72
AU - Australia 69
SA - Arabia Saudita 61
CO - Colombia 57
CL - Cile 54
EG - Egitto 53
GR - Grecia 50
UZ - Uzbekistan 45
LB - Libano 44
LT - Lituania 44
MY - Malesia 43
VE - Venezuela 42
CZ - Repubblica Ceca 41
PY - Paraguay 38
EU - Europa 36
MA - Marocco 36
IL - Israele 35
RO - Romania 34
TN - Tunisia 29
PT - Portogallo 25
PE - Perù 23
AE - Emirati Arabi Uniti 21
UY - Uruguay 21
DZ - Algeria 20
HR - Croazia 19
KE - Kenya 19
JM - Giamaica 18
KZ - Kazakistan 17
NP - Nepal 17
RS - Serbia 16
AZ - Azerbaigian 14
ET - Etiopia 14
SN - Senegal 14
AL - Albania 13
DK - Danimarca 13
OM - Oman 13
LV - Lettonia 12
CR - Costa Rica 11
GT - Guatemala 11
HN - Honduras 11
NO - Norvegia 11
HU - Ungheria 10
KG - Kirghizistan 10
NZ - Nuova Zelanda 10
TT - Trinidad e Tobago 9
CY - Cipro 8
DO - Repubblica Dominicana 8
PA - Panama 8
QA - Qatar 8
SY - Repubblica araba siriana 8
BO - Bolivia 7
BY - Bielorussia 7
NI - Nicaragua 7
PS - Palestinian Territory 7
GH - Ghana 6
MK - Macedonia 6
Totale 92.884
Salva come PNG Salva come JPEG
Città #
Singapore 6.071
Southend 4.046
Ashburn 3.782
Fairfield 3.092
Chandler 2.439
San Jose 2.040
Ho Chi Minh City 1.988
Hong Kong 1.960
Hanoi 1.672
Hefei 1.568
Woodbridge 1.405
Seattle 1.358
Houston 1.305
Wilmington 1.283
Dong Ket 1.151
Beijing 1.124
Cambridge 1.080
Princeton 1.040
Ann Arbor 969
Santa Clara 961
Bologna 935
Dublin 815
Boardman 764
Seoul 725
Lauterbourg 639
New York 557
Dallas 553
Los Angeles 539
Helsinki 525
Abidjan 476
Tokyo 405
Milan 388
Nanjing 377
Westminster 374
Lomé 365
Council Bluffs 355
Berlin 322
Padova 299
Buffalo 296
Frankfurt am Main 247
Haiphong 246
São Paulo 244
Jacksonville 234
Da Nang 223
Jinan 220
Bremen 219
Sofia 211
Redondo Beach 207
Amman 205
San Diego 202
Shenyang 198
Munich 194
Turin 189
Rome 188
Redmond 177
Saint Petersburg 177
Guangzhou 164
Shanghai 156
Nuremberg 155
Changsha 149
Bengaluru 148
Brussels 144
Redwood City 141
Tianjin 138
Jakarta 137
London 136
Hyderabad 132
Bern 126
Chicago 125
Toronto 120
Zhengzhou 119
Hebei 117
Nanchang 116
Florence 113
Amsterdam 108
Des Moines 107
Vienna 105
Johannesburg 104
Abeokuta 103
Medford 99
Hangzhou 94
Phoenix 93
Paris 91
Biên Hòa 90
Warsaw 89
Lappeenranta 88
Orem 87
Jiaxing 84
Hải Dương 83
Falkenstein 77
Norwalk 75
Can Tho 73
Atlanta 71
Quận Bình Thạnh 70
Brooklyn 69
Olalla 69
The Dalles 69
Montreal 66
Thái Nguyên 66
Dearborn 64
Totale 58.254
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 711
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 662
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma 479
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 390
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 389
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 349
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 324
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 320
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 317
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 311
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 310
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 305
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 295
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 287
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 283
Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation 278
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 270
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 268
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 267
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 263
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 263
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 251
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 249
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 247
A NEW RISK STRATIFICATION STRATEGY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN ANALYSIS ON MATURE DATA FROM EUROPEAN CLINICAL TRIALS WITHIN THE HARMONY BIG DATA PLATFORM 239
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 237
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 237
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 236
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 235
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 233
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma 232
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 232
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 232
A new risk stratification model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 patients collected by European Myeloma Network Within HARMONY Big Data Platform 232
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 232
ATP release from chemotherapy-treated dying leukemia cells Elicits an immune suppressive effect by increasing regulatory T cells and Tolerogenic dendritic cells 230
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 230
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 230
Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients 229
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 229
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 229
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 229
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 228
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 227
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 226
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 226
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 224
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 222
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 222
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 222
Assessmen of disease ativity in multiple myeloma with FDG-PET imaging 221
Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation 221
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 221
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 220
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 220
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 219
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 217
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 217
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 215
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 214
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 214
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 213
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 213
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 213
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 213
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 212
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 212
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 211
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 211
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 210
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 210
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 210
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? 209
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 209
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 209
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 208
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 208
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 208
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 208
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 208
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 207
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 207
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 206
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 206
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 205
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 204
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 204
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 203
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 203
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 203
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 203
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 203
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 203
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 202
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 202
Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. 202
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 201
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 200
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 200
Totale 24.540
Salva come PNG Salva come JPEG
Categoria #
all - tutte 270.578
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 270.578
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.509 0 0 0 0 0 0 0 0 0 0 0 2.509
2021/20229.085 815 313 534 706 852 456 205 721 411 685 1.810 1.577
2022/202310.574 1.111 1.517 538 1.445 757 801 360 630 1.759 341 810 505
2023/20243.629 234 526 260 341 301 680 207 287 150 256 213 174
2024/202514.419 614 2.032 1.244 1.077 1.620 721 1.178 571 344 1.261 960 2.797
2025/202635.353 2.972 4.348 3.123 2.792 3.341 1.866 3.182 1.719 6.561 2.619 1.612 1.218
Totale 94.875